-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
2021 Nian 4 Yue 8 days, Baiji China announced the biopharmaceutical production base in Guangzhou, the commercial production of officially approved.
2021 Nian 4 Yue 8 days, Baiji China announced the biopharmaceutical production base in Guangzhou, the commercial production of officially approved.
It is reported that the cumulative total investment in the construction of the Guangzhou factory totals 2.
The commercial production of BeiGene Guangzhou Biopharmaceutical Production Base was approved and the commercial supply celebration ceremony started
The commercial production of BeiGene Guangzhou Biopharmaceutical Production Base was approved and the commercial supply celebration ceremony startedTilelizumab injection is the first drug developed by BeiGene's immuno-oncology platform.
Tilelizumab injection is the first drug developed by BeiGene's immuno-oncology platform.
In China, the National Medical Products Administration ( NMPA ) of China has approved Baizean® combined with chemotherapy for the treatment of patients with first-line advanced squamous non-small cell lung cancer ( NSCLC ).
In addition, 1 Yue 12 Ri, NMPA has approved its anti- PD-1 antibody Chak one hundred ® ( tislelizumab , for Reilly natalizumab injection) joint 2 Xiang chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer ( NSCLC )patient.
The approval of the new indication is based on the results of a phase 3 clinical trial ( NCT03594747 ).
Dr.
At present, China Baiji two independent research and development of drugs, BTK inhibitors Perrier Chak ® (imatinib Zerbe capsules) is the United States and China to sell, anti- PD-1 antibody drug Chak one hundred ® (natalizumab for Raleigh Injection) is sold in China.
When asked about the availability of global drugs, Mr.
Michael Garvey , Head of Global Technical Operations of BeiGene , said: “ BeiGene has become the first biologic drug approved for commercial production of anti- PD-1 antibodies in Guangdong Province.
Factory.
The construction of the Guangzhou factory’s autonomous capabilities can also benefit our business partners, enabling them to benefit from our full range of services in development, production and commercialization.
Considering the continuity of production, we will not give up on the Work mode.
"
Leave a message here
